Both in Biotechnology
Voyager Therapeutics vs Humacyte
Over the past year VYGR returned −61.2% and HUMA returned −75.0%; their daily moves had a correlation of 0.21.
VYGR −61.2% HUMA −75.0%Growth of $1, one year, split-adjusted
| Metric | VYGR | HUMA |
|---|---|---|
| Price | $1.78 | $0.3981 |
| Market cap | $109.7M | $110.6M |
| Today | +3.49% | −3.19% |
| 1 month | −27.3% | −23.7% |
| 6 months | −54.1% | −57.0% |
| Year to date | −54.7% | −58.6% |
| 1 year | −60.6% | −75.4% |
| Revenue growth (YoY) | −39.1% | +34.9% |
| Gross margin | 100.0% | −203.2% |
| Net margin | −773.2% | −9064.5% |
| P/E (TTM) | — | — |
| Price / sales | 3.2× | 52.1× |
| Net cash | $116.3M | $13.7M |
| Dividend yield | — | — |
| Volatility (60d) | 60.6% | 106.0% |
| Short % of float | 7.8% | 11.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).